ERBB2 and ductal breast carcinoma in situ: Lapatinib also reduces mammosphere-formation and proliferation of BCSCs in both HER2+ and HER2-normal ductal carcinoma in situ (DCIS) cell lines as well as in DCIS cells derived from patient samples.